Cardinal Health, Inc. (CAH) is an American multinational health care services company that provides a broad range of services to pharmacies, hospitals, ambulatory surgery centers, clinical laboratories, and physician offices globally. The company's operations are divided into two segments: Pharmaceutical and Medical, each carrying out various specialized activities.
The Pharmaceutical segment distributes a vast range of national brand, generic pharmaceuticals, specialty pharmaceuticals, and over-the-counter healthcare and consumer products in the United States. They operate the world's largest network of nuclear pharmacies and are expanding their positron emission tomography (PET) radiopharmaceutical dispensing network to meet the growing needs of health care providers.
The Medical segment manufactures, sources, and distributes Cardinal Health's label medical, laboratory, and surgical products and services through hospital direct, integrated delivery networks, independent healthcare distributors, and the company's e-commerce platform, cardinal.com.
Established in 1971, Cardinal Health has its headquarters in Dublin, Ohio. As of today, it ranks 16th on the Fortune 500 list and is regarded as one of the highest revenue-generating companies in the United States. Over the years, the company has acquired numerous businesses, significantly broadening its scope and capabilities.
Cardinal Health works with stakeholders to make healthcare safer while ensuring costs are effectively managed for its approximately 100 million customers. The company provides clinically proven medical products, pharmaceuticals, and cost-effective solutions that enhance supply chain efficiency from hospital to home.
Key to Cardinal Health's business model is their commitment to transform healthcare with innovative solutions. Their expertise in pharmaceutical distribution and supply chain management allows them to address unique challenges in healthcare delivery. With nearly 50,000 employees worldwide, Cardinal Health is essential in making healthcare more efficient, thereby helping customers thrive in a changing world.
In summary, Cardinal Health, Inc. (CAH) is a crucial player in the global healthcare sector with a relentless commitment to delivering value to clients while advancing health and wellness for people around the world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Alcon's third-quarter sales increased by 5% to $2.7 billion, but implantables experienced a 2% decline due to heightened competition in the US premium IOL market. To counter this, Alcon is relying on its new Vivity Pro lens, launching in January, an RxSight license, and the recent Neurotech acquisition to stimulate growth and outpace the estimated 3% market expansion. The company aims to restore growth in its implantables business after losing US premium intraocular lens share.
Cardinal Health (CAH) stock is on a 6-day winning streak, gaining 9.7% and adding approximately $5.7 billion to its market value, now at $64.4 billion. This surge is primarily driven by company-specific factors rather than broader market movements, with the stock closing at $277.45, its highest in the past year. While revenue growth is strong, operating margins are below the S&P 500 Health Care median.
Cardinal Health's Board of Directors has approved a quarterly dividend of $0.5158 per share, payable on January 15, 2027, to shareholders of record as of January 4, 2027. The dividend will be issued from the company's capital surplus. Cardinal Health is a global healthcare services and products company, providing customized solutions across the healthcare industry.
Cardinal Health (CAH) has shown strong long-term performance, but its current stock valuation appears rich, trading at 35.3x earnings, which is above the sector average. Recent positive results and raised earnings guidance have pushed the stock to a 52-week high, suggesting much of the good news is already factored into the price. While analysts generally view the stock as "roughly fairly valued" based on its earnings power and cash generation, the premium valuation warrants careful consideration.
Cardinal Health's Board of Directors has approved a quarterly dividend of $0.5158 per share, payable on January 15, 2027, to shareholders of record as of January 4, 2027. This decision reflects the company's strong capital management and commitment to shareholder returns. Cardinal Health, a global distributor of pharmaceuticals and medical products, aims to enhance investor confidence and solidify relationships with its shareholders.
This article examines the safety of Cardinal Health's (NYSE:CAH) dividend, which is favored by Jim Cramer and listed among his top dividend stocks. Despite a small recent dividend increase, the company's strong operating cash flow, even after accounting for litigation payments, suggests its dividend is secure. The analysis compares Cardinal Health's dividend sustainability to other consumer and pipeline stocks Cramer has discussed, highlighting cash flow as a key indicator.
CVS recently announced a corporate split into CVS Health and CVS Pharmacy, aiming for increased focus and better customer experience, with completion expected by 2028. However, critics like Antonio Ciaccia argue that the breakup primarily separates less profitable retail operations from lucrative pharmacy benefit management (PBM) and insurance sectors, including high-profit specialty drugs, without addressing core conflicts of interest in healthcare costs. The American Economic Liberties Project views it as an attempt to preempt more substantial reforms, though some believe it eliminates conflicts related to PBM reimbursements to independent pharmacies.
Cardinal Health (NYSE: CAH) has significantly outperformed the market over the last five years, with an annualized return of 40.55%. An investment of $100 in CAH stock five years ago would now be worth $538.08, demonstrating the power of compounded returns. The company currently holds a market capitalization of $63.40 billion.